CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric
antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological
malignancies.